NASDAQ:SRRA - Sierra Oncology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.35 -0.01 (-0.74 %) (As of 01/16/2019 04:00 PM ET)Previous Close$1.36Today's Range$1.34 - $1.4052-Week Range$1.05 - $3.70Volume71,900 shsAverage Volume181,864 shsMarket Capitalization$101.88 millionP/E Ratio-1.61Dividend YieldN/ABeta1.68 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Receive SRRA News and Ratings via Email Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRRA Previous SymbolNASDAQ:DNAI CUSIPN/A Webwww.sierraoncology.com Phone604-558-6536Debt Debt-to-Equity Ratio0.05 Current Ratio14.68 Quick Ratio14.68Price-To-Earnings Trailing P/E Ratio-1.61 Forward P/E Ratio-1.75 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.81 per share Price / Book0.75Profitability EPS (Most Recent Fiscal Year)($0.84) Net Income$-42,010,000.00 Net MarginsN/A Return on Equity-43.82% Return on Assets-40.76%Miscellaneous Employees57 Outstanding Shares74,370,000Market Cap$101.88 million OptionableOptionable Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions What is Sierra Oncology's stock symbol? Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA." How were Sierra Oncology's earnings last quarter? Sierra Oncology Inc (NASDAQ:SRRA) announced its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.03. View Sierra Oncology's Earnings History. When is Sierra Oncology's next earnings date? Sierra Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Sierra Oncology. Has Sierra Oncology been receiving favorable news coverage? News articles about SRRA stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Sierra Oncology earned a news sentiment score of -1.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. Who are some of Sierra Oncology's key competitors? Some companies that are related to Sierra Oncology include Arcus Biosciences (RCUS), MediciNova (MNOV), Progenics Pharmaceuticals (PGNX), ArQule (ARQL), Cytokinetics (CYTK), Kindred Biosciences (KIN), Synthorx (THOR), TG Therapeutics (TGTX), Sinovac Biotech (SVA), Xeris Pharmaceuticals (XERS), Rigel Pharmaceuticals (RIGL), Akebia Therapeutics (AKBA), Kalvista Pharmaceuticals (KALV), Keryx Biopharmaceuticals (KERX) and Abeona Therapeutics (ABEO). Who are Sierra Oncology's key executives? Sierra Oncology's management team includes the folowing people: Dr. Nicholas R. Glover, Pres, CEO & Director (Age 50)Dr. Barbara Klencke, Chief Devel. Officer (Age 62)Dr. Mark M. Kowalski, Chief Medical Officer (Age 64)Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 45)Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 50) How do I buy shares of Sierra Oncology? Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sierra Oncology's stock price today? One share of SRRA stock can currently be purchased for approximately $1.35. How big of a company is Sierra Oncology? Sierra Oncology has a market capitalization of $101.88 million. The biotechnology company earns $-42,010,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Sierra Oncology employs 57 workers across the globe. What is Sierra Oncology's official website? The official website for Sierra Oncology is http://www.sierraoncology.com. How can I contact Sierra Oncology? Sierra Oncology's mailing address is 2150 -885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected] MarketBeat Community Rating for Sierra Oncology (NASDAQ SRRA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 182 (Vote Outperform)Underperform Votes: 164 (Vote Underperform)Total Votes: 346MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe SRRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/16/2019 by MarketBeat.com StaffFeatured Article: What is Compound Interest?